| pubmed-article:20455760 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:20455760 | lifeskim:mentions | umls-concept:C0019682 | lld:lifeskim |
| pubmed-article:20455760 | lifeskim:mentions | umls-concept:C0019699 | lld:lifeskim |
| pubmed-article:20455760 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:20455760 | lifeskim:mentions | umls-concept:C0332307 | lld:lifeskim |
| pubmed-article:20455760 | lifeskim:mentions | umls-concept:C0012133 | lld:lifeskim |
| pubmed-article:20455760 | lifeskim:mentions | umls-concept:C0209738 | lld:lifeskim |
| pubmed-article:20455760 | lifeskim:mentions | umls-concept:C0036043 | lld:lifeskim |
| pubmed-article:20455760 | lifeskim:mentions | umls-concept:C1145759 | lld:lifeskim |
| pubmed-article:20455760 | lifeskim:mentions | umls-concept:C0205195 | lld:lifeskim |
| pubmed-article:20455760 | lifeskim:mentions | umls-concept:C0036644 | lld:lifeskim |
| pubmed-article:20455760 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:20455760 | pubmed:dateCreated | 2010-5-18 | lld:pubmed |
| pubmed-article:20455760 | pubmed:abstractText | The use of ritonavir as a protease inhibitor boost is rare in sub-Saharan Africa because a heat-stable formula is not available. We report the results of an open-label pilot trial with unboosted atazanavir in combination with lamivudine and didanosine as first-line therapy conducted in Senegal. Treatment-naive HIV-1 infected adult patients without active opportunistic disease were included. The primary endpoint was the proportion of patients with plasma HIV-1 RNA <400 copies/ml at week 48. Forty patients (12 men and 28 women; mean age +/- SD: 40 +/- 9 years) were included. Treatment was changed during the study for two patients (pregnancy, tuberculosis); one patient was lost to follow-up and one patient died (gastroenteritis with cachexia). At week 48, 78% [95% confidence interval (CI): 65-90%] and 68% (95% CI: 53-82%) of the patients had HIV-1 RNA <400 and <50 copies/ml, respectively (intent-to-treat analysis; not completer = failure). Among the seven patients with HIV-1 RNA >or=400 copies/ml at week 48, five were not compliant; genotyping analysis (n = 4) did not reveal a major mutation for protease inhibitors. The mean CD4 cell count change from baseline to week 48 was +238 +/- 79 cells/mm(3). The combination of unboosted atazanavir with lamivudine and didanosine was efficient and well tolerated in HIV-1-infected patients with results similar to those observed in Northern countries. These results suggest that unboosted atazanavir with its high genetic barrier could be a valuable alternative to NNRTIs in resource-limited countries in some HIV-1-infected patients in case of compliance issues with NNRTIs, intolerance to NNRTIs, resistance mutations to NNRTIs, in women with childbearing potential, or as a maintenance therapy in patients with virological suppression. | lld:pubmed |
| pubmed-article:20455760 | pubmed:language | eng | lld:pubmed |
| pubmed-article:20455760 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20455760 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:20455760 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20455760 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20455760 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20455760 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20455760 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20455760 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20455760 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20455760 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20455760 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:20455760 | pubmed:month | May | lld:pubmed |
| pubmed-article:20455760 | pubmed:issn | 1931-8405 | lld:pubmed |
| pubmed-article:20455760 | pubmed:author | pubmed-author:NdiayeBB | lld:pubmed |
| pubmed-article:20455760 | pubmed:author | pubmed-author:MboupSS | lld:pubmed |
| pubmed-article:20455760 | pubmed:author | pubmed-author:VozM LML | lld:pubmed |
| pubmed-article:20455760 | pubmed:author | pubmed-author:GirardP MPM | lld:pubmed |
| pubmed-article:20455760 | pubmed:author | pubmed-author:PeytavinGG | lld:pubmed |
| pubmed-article:20455760 | pubmed:author | pubmed-author:DialloM BMB | lld:pubmed |
| pubmed-article:20455760 | pubmed:author | pubmed-author:BennatDD | lld:pubmed |
| pubmed-article:20455760 | pubmed:author | pubmed-author:LandmanRoland... | lld:pubmed |
| pubmed-article:20455760 | pubmed:author | pubmed-author:BenalycherifA... | lld:pubmed |
| pubmed-article:20455760 | pubmed:author | pubmed-author:KaneC ToureCT | lld:pubmed |
| pubmed-article:20455760 | pubmed:author | pubmed-author:GueyeN F... | lld:pubmed |
| pubmed-article:20455760 | pubmed:author | pubmed-author:FallM B... | lld:pubmed |
| pubmed-article:20455760 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:20455760 | pubmed:volume | 26 | lld:pubmed |
| pubmed-article:20455760 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:20455760 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:20455760 | pubmed:pagination | 519-25 | lld:pubmed |
| pubmed-article:20455760 | pubmed:meshHeading | pubmed-meshheading:20455760... | lld:pubmed |
| pubmed-article:20455760 | pubmed:meshHeading | pubmed-meshheading:20455760... | lld:pubmed |
| pubmed-article:20455760 | pubmed:meshHeading | pubmed-meshheading:20455760... | lld:pubmed |
| pubmed-article:20455760 | pubmed:meshHeading | pubmed-meshheading:20455760... | lld:pubmed |
| pubmed-article:20455760 | pubmed:meshHeading | pubmed-meshheading:20455760... | lld:pubmed |
| pubmed-article:20455760 | pubmed:meshHeading | pubmed-meshheading:20455760... | lld:pubmed |
| pubmed-article:20455760 | pubmed:meshHeading | pubmed-meshheading:20455760... | lld:pubmed |
| pubmed-article:20455760 | pubmed:meshHeading | pubmed-meshheading:20455760... | lld:pubmed |
| pubmed-article:20455760 | pubmed:meshHeading | pubmed-meshheading:20455760... | lld:pubmed |
| pubmed-article:20455760 | pubmed:meshHeading | pubmed-meshheading:20455760... | lld:pubmed |
| pubmed-article:20455760 | pubmed:meshHeading | pubmed-meshheading:20455760... | lld:pubmed |
| pubmed-article:20455760 | pubmed:meshHeading | pubmed-meshheading:20455760... | lld:pubmed |
| pubmed-article:20455760 | pubmed:meshHeading | pubmed-meshheading:20455760... | lld:pubmed |
| pubmed-article:20455760 | pubmed:meshHeading | pubmed-meshheading:20455760... | lld:pubmed |
| pubmed-article:20455760 | pubmed:meshHeading | pubmed-meshheading:20455760... | lld:pubmed |
| pubmed-article:20455760 | pubmed:meshHeading | pubmed-meshheading:20455760... | lld:pubmed |
| pubmed-article:20455760 | pubmed:meshHeading | pubmed-meshheading:20455760... | lld:pubmed |
| pubmed-article:20455760 | pubmed:meshHeading | pubmed-meshheading:20455760... | lld:pubmed |
| pubmed-article:20455760 | pubmed:meshHeading | pubmed-meshheading:20455760... | lld:pubmed |
| pubmed-article:20455760 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:20455760 | pubmed:articleTitle | Efficacy and safety of unboosted atazanavir in combination with lamivudine and didanosine in naive HIV type 1 patients in Senegal. | lld:pubmed |
| pubmed-article:20455760 | pubmed:affiliation | Institut de Médecine et d'Epidémiologie Appliquée, Service des Maladies Infectieuses et Tropicales, Bichat Claude-Bernard Hospital, Paris Cedex 18, France. roland.landman@univ-paris-diderot.fr | lld:pubmed |
| pubmed-article:20455760 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:20455760 | pubmed:publicationType | Clinical Trial | lld:pubmed |
